Related Experiment Videos
Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell
1Institute of Biological Science, Mitsui Pharmaceuticals, Inc., Chiba, Japan.
Abstract:
A novel quinoline compound, MS-209, was examined for its ability to reverse multidrug resistance (MDR) in several murine and human MDR solid tumor cell lines both in vitro and in vivo. MS-209 strongly reversed drug resistance to adriamycin (ADM) and vincristine (VCR) in acquired MDR tumor cell lines, 2780AD and KB-C1. In addition, MS-209 enhanced the cytotoxic effect of ADM and VCR on various human and murine cell lines. Particularly in 4-1St cells, which are extremely resistant to ADM and VCR, MS-209 at a concentration of 3 microM enhanced the cytotoxicity of ADM and VCR, 88- and 350-fold, respectively. MS-209 administered orally, together with ADM, enhanced the antitumor activity of ADM on Colon 26 and 4-1St tumors implanted subcutaneously (SC) in mice; the antitumor effect of ADM plus MS-209 was higher than that of ADM alone at the maximum tolerated dose (MTD). Furthermore, the coadministration schedules of MS-209 to attain the highest potentiation of ADM activity were examined using Colon 26 tumors. The maximum antitumor activity was obtained when MS-209 was administered on the same day as ADM. MS-209 administered a day before the ADM injection exhibited no potentiation effect, whereas MS-209 administered a day after the ADM injection showed a moderate effect. The effect of MS-209 was weaker when administered in a fractionated manner than when administered as a single dose. The results presented in this article suggest that MS-209 is an effective agent to overcome MDR in cancer chemotherapy.
Insights
A novel compound, MS-209, effectively reverses multidrug resistance (MDR) in cancer cells, enhancing chemotherapy drug efficacy. This quinoline derivative shows promise in overcoming resistance to adriamycin and vincristine in various solid tumors.
Area of Science:
- Pharmacology
- Oncology
- Medicinal Chemistry
Background:
- Multidrug resistance (MDR) significantly limits the effectiveness of cancer chemotherapy.
- Acquired resistance to agents like adriamycin (ADM) and vincristine (VCR) is a major clinical challenge.
- Novel compounds are needed to overcome MDR and improve treatment outcomes.
Purpose of the Study:
- To evaluate the efficacy of a novel quinoline compound, MS-209, in reversing MDR in solid tumor cell lines.
- To assess the in vitro and in vivo activity of MS-209 in combination with chemotherapy drugs.
- To determine optimal administration schedules for MS-209 to maximize its potentiating effect.
Main Methods:
- In vitro testing of MS-209 on murine and human MDR solid tumor cell lines (e.g., 2780AD, KB-C1, 4-1St).
- In vivo studies involving subcutaneous tumor implantation in mice (Colon 26, 4-1St) treated with MS-209 and ADM.
- Evaluation of different coadministration schedules for MS-209 and ADM.
Main Results:
- MS-209 significantly reversed resistance to adriamycin (ADM) and vincristine (VCR) in acquired MDR cell lines.
- MS-209 enhanced the cytotoxic effects of ADM and VCR, with notable potentiation in highly resistant 4-1St cells (88-fold for ADM, 350-fold for VCR).
- Oral administration of MS-209 with ADM improved antitumor activity in mice, outperforming ADM alone at maximum tolerated dose; same-day administration yielded the best results.
Conclusions:
- MS-209 demonstrates potent MDR-reversing capabilities in preclinical models.
- The compound enhances the efficacy of key chemotherapy agents against resistant solid tumors.
- MS-209 represents a promising therapeutic strategy for overcoming drug resistance in cancer chemotherapy.